每年研究成果
每年研究成果
- 4結果
搜尋結果
-
2024
Correction: CHRM4/AKT/MYCN upregulates interferon alpha-17 in the tumor microenvironment to promote neuroendocrine differentiation of prostate cancer (Cell Death & Disease, (2023), 14, 5, (304), 10.1038/s41419-023-05836-7)
Wen, Y. C., Tram, V. T. N., Chen, W. H., Li, C. H., Yeh, H. L., Thuy Dung, P. V., Jiang, K. C., Li, H. R., Huang, J., Hsiao, M., Chen, W. Y. & Liu, Y. N., 1月 2024, 於: Cell Death and Disease. 15, 1, 92.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
2020
Correction: ZBTB46, SPDEF, ETV6 novel potential biomarkers and therapeutic targets in castration resistance prostate cancer (Int. j. mol. sci. (2019), 20, 2802, 10.3390/ijms20112802)
Fararjeh, A. F. S. & Liu, Y. N., 6月 2 2020, 於: International journal of molecular sciences. 21, 12, p. 1 1 p., 4243.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取 -
2019
Erratum: RAB14 activates MAPK signaling to promote bladder tumorigenesis (Carcinogenesis (bgz039) DOI: 10.1093/carcin/bgz039)
Chao, H., Deng, L., Xu, F., Fu, B., Zhu, Z., Dong, Z., Liu, Y. N. & Zeng, T., 9月 1 2019, 於: Carcinogenesis. 40, 9, p. 1177 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
開啟存取1 引文 斯高帕斯（Scopus） -
2018
Correction: Loss of EGFR signaling-regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance [Oncotarget. 5, (2014), 3770-3784]doi 10.18632/oncotarget.1994
Siu, M. K., Abou-Kheir, W., Yin, J. J., Chang, Y. S., Barrett, B., Suau, F., Casey, O., Chen, W. Y., Fang, L., Hynes, P., Hsieh, Y. Y., Liu, Y. N., Huang, J. & Kelly, K., 8月 17 2018, 於: Oncotarget. 9, 64, p. 32403 1 p.研究成果: 雜誌貢獻 › 評論/辯論 › 同行評審
4 引文 斯高帕斯（Scopus）